Detailed phase 3 results from two Islend clinical trials confirmed that a once-weekly, single-tablet combination of Merck’s islatravir and Gilead’s lenacapavir matches daily treatments like Biktarvy at maintaining HIV viral suppression
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
